Dana-Farber

A historic moment at #ASCO26: more than 9,000 oncologists rose for three standing ovations as Brian Wolpin, MD, MPH, Director of the Hale Family Center for Pancreatic Cancer Research, presented promising new Phase 3 results for an investigational treatment for metastatic pancreatic cancer.

In the trial, daraxonrasib helped patients with previously treated metastatic pancreatic cancer live significantly longer than those who received chemotherapy.

While more work remains, these findings offer something powerful: hope for patients and families facing one of the most challenging cancers.

As Dr. Wolpin said, “It is exciting to see that we may soon be able to help patients with metastatic pancreatic cancer in ways we haven’t been able to before, improving both survival and quality of life.”

Congratulations to the researchers and patients who made this important progress possible. 👏👏👏

Video Courtesy: @asco

Congratulations to Philip Kranzusch, PhD, on receiving the 2026 Richard A. Smith Excellence in Biomedical Research Alumni Prize from the Richard and Susan Smith Family Foundation for his groundbreaking discoveries about the origins of human innate immunity and the molecular mechanisms by which cells recognize and defend against infection and cancer. Read more. ⬇️ bit.ly/48DldZd

.@DFCI_BreastOnc is leading the future of breast cancer treatment and care through innovation, collaboration, and delivering state-of-the-art patient care.

@stolaney1, MD, MPH, chief of Breast Oncology and associate director of the Susan F. Smith Center for Women’s Cancers and Elizabeth Mittendorf, MD, PhD, MHCM, chief of Multi-Disciplinary Oncology at Dana-Farber and of Breast Surgery in the Department of Surgery at @BIDMChealth, and @ASCOPres, discuss the future of breast cancer research and treatment.

Get their take on what's next: bit.ly/4kA2F3j

Two emerging cancer therapies, daraxonrasib and revumenib, have been named to @TIME's Best Inventions of 2026 list.

From foundational scientific discoveries to clinical research, we’re proud to have helped drive the progress behind both therapies. Learn more about each breakthrough: bit.ly/4iVbZfZ and bit.ly/3V2bvwn

New clues to how follicular lymphoma turns aggressive. Our researchers uncovered key changes in surrounding cells that could help detect the transition earlier and improve treatments for patients. 🔗⬇️ bit.ly/4sjN5L9